CytomX Therapeutics (NASDAQ:CTMX) Stock Lifted to Hold by Wall Street Zen

Key Points

• Wall Street Zen upgraded CytomX from “sell” to “hold.” Despite mixed analyst views, MarketBeat reports a “Moderate Buy” consensus rating and a $12 average price target.
• Quarterly results missed expectations: CytomX reported $1.69 million in revenue versus $10.38 million expected and a loss of $0.09 per share, $0.02 worse than consensus.
• Varseta-M showed reported response rates of 20%–32% in late-line colorectal cancer, with pivotal-trial initiation planned for the first half of 2027; the program’s development outlook carries execution risk.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Saturday, Wall Street Zen reports.

CTMX has been the subject of a number of other research reports. Weiss Ratings reiterated a "sell (d)" rating on shares of CytomX Therapeutics in a research note on Friday, September 11th. Zacks Research lowered CytomX Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 19th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of CytomX Therapeutics in a report on Tuesday, October 13th. Wedbush raised their price target on shares of CytomX Therapeutics from $11.00 to $12.00 and gave the company an "outperform" rating in a research report on Friday. Finally, JPMorgan Chase & Co. reduced their target price on CytomX Therapeutics from $12.00 to $11.00 and set an "overweight" rating for the company in a research note on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, CytomX Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $12.00.

CytomX Therapeutics Trading Up 2.3%

CTMX opened at $2.19 on Friday. The stock has a 50-day moving average of $2.71 and a 200 day moving average of $3.81. CytomX Therapeutics has a 12 month low of $2.11 and a 12 month high of $8.21.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last released its earnings results on Thursday, November 5th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.02). CytomX Therapeutics had a negative net margin of 435.21% and a negative return on equity of 38.46%. The firm had revenue of $1.69 million during the quarter, compared to analysts' expectations of $10.38 million. On average, analysts expect that CytomX Therapeutics will post -0.40 earnings per share for the current year.

Institutional Trading of CytomX Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CTMX. Bank of America Corp DE boosted its position in shares of CytomX Therapeutics by 1,064.3% during the 1st quarter. Bank of America Corp DE now owns 10,202,785 shares of the biotechnology company's stock valued at $47,953,000 after acquiring an additional 9,326,480 shares during the last quarter. Canada Pension Plan Investment Board acquired a new position in CytomX Therapeutics during the 2nd quarter worth $531,000. Wellington Management Group LLP boosted its position in shares of CytomX Therapeutics by 44.3% during the 2nd quarter. Wellington Management Group LLP now owns 5,168,961 shares of the biotechnology company's stock worth $19,384,000 after purchasing an additional 1,585,976 shares in the last quarter. Stonepine Capital Management LLC acquired a new position in CytomX Therapeutics during the second quarter valued at approximately $768,750. Finally, BlackRock Inc. bought a new stake in CytomX Therapeutics in the 2nd quarter valued at about $65,849,000. 67.77% of the stock is owned by institutional investors.

More CytomX Therapeutics News

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Wedbush raised its price target to $12 from $11 and maintained an Outperform rating, signaling continued optimism about CytomX’s prospects. Wedbush Raises Price Target
• Positive Sentiment: Varseta-M reported 20%–32% objective response rates and a seven-month median progression-free survival in late-line colorectal cancer. The program has FDA Fast Track designation, with pivotal-trial initiation planned for the first half of 2027. The company also had $367 million in cash and potential partnership milestones, although those milestones are contingent on future development and commercial progress. CytomX Stock Trading Near Cash Value
• Negative Sentiment: Third-quarter revenue was $1.69 million, well below analyst expectations of $10.38 million. CytomX reported a loss of $0.09 per share; one report characterized this as a $0.02-per-share miss against its consensus estimate. The revenue shortfall and continuing losses may weigh on sentiment. CytomX Q3 Results
• Negative Sentiment: The clinical-program outlook carries execution risk, and the cited analysis notes prior dilution and terminated legacy partnerships as concerns that have pressured revenue. CytomX Stock Trading Near Cash Value

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing cancer medicines designed to be activated selectively within the tumor microenvironment. The company's approach is intended to improve the precision of treatment by limiting activity in healthy tissues while enabling therapeutic effects at tumor sites.

CytomX's research is based on its Probody therapeutic platform, which uses molecular masking and tumor-associated protease activity to conditionally activate antibody-based medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.